NASDAQ:CTMX | Free Cash Flow | CytomX Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$25.55M$0.00-$25.55M
2025-12-31-$23.24M$201,000.00-$23.44M
2025-03-31-$21.04M$119,000.00-$21.16M-89.96%
2024-12-31-$19.91M$80,000.00-$19.99M-105.89%
2024-03-31-$26.05M$115,000.00-$26.16M-189.69%
2023-12-31-$21.96M$266,000.00-$22.23M-2655.79%
2023-03-31$9.35M$48,000.00$9.3M
2022-12-31-$1.39M$182,000.00-$1.58M
2022-03-31-$41.31M$736,000.00-$42.05M
2021-12-31-$31.19M$245,000.00-$31.44M
2021-03-31-$29.94M$982,000.00-$30.92M
2020-12-31-$17.43M$445,000.00-$17.87M
2020-03-31-$49.74M$1.05M-$50.79M-416.11%
2019-12-31-$29.48M$703,000.00-$30.18M
2019-03-31-$39.03M$1.84M-$40.86M
2018-12-31-$28.74M$1.12M-$29.86M
2018-03-31-$14.61M$751,000.00-$15.36M
2017-12-31$22M$234,000.00$21.77M3505.31%
2017-03-31-$19.09M$944,000.00-$20.03M
2016-12-31$1.94M$602,000.00$1.33M
2016-03-31-$5.54M$327,000.00-$5.87M
2015-12-31-$8.17M$182,000.00-$8.35M
2015-03-31-$5.37M$255,000.00-$5.62M
2014-12-31-$4.4M$664,000.00-$5.06M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$75.59M$220,000.00-$75.81M
2024-12-31-$86.23M$310,000.00-$86.54M-271.55%
2023-12-31-$56.04M$840,000.00-$56.88M
2022-12-31-$110.79M$1.74M-$112.53M
2021-12-31-$119.03M$1.61M-$120.64M
2020-12-31$5.26M$2.31M$2.95M
2019-12-31-$140.48M$3.5M-$143.98M
2018-12-31-$75.52M$3.79M-$79.31M
2017-12-31$170.37M$1.56M$168.81M
2016-12-31-$2.03M$2.18M-$4.21M
2015-12-31-$27.42M$1.59M-$29.01M
2014-12-31$31.8M$1.66M$30.14M
2013-12-31-$8.01M$732,000.00-$8.74M